Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Professor Sir Philip Cohen Receives MRC Millennium Medal

Published: Friday, March 01, 2013
Last Updated: Thursday, February 28, 2013
Bookmark and Share
Professor Sir Gregory Winter of the University of Cambridge also receives medal from MRC.

Professor Sir Philip Cohen, of the University of Dundee, has received the highest award given by the Medical Research Council at a ceremony in the House of Commons on Wednesday February 27th.

The Millennium Medal is the MRC’s most prestigious award, presented every two years to an outstanding scientist who has made a major contribution towards the MRC’s mission to improve human health through world class medical research.

This year the MRC are presenting two medals, to Sir Philip and to Professor Sir Gregory Winter, of the University of Cambridge.

Professor Sir John Savill, Chief Executive of the MRC, said, “The MRC is proud to award this year’s Millennium Medal to Sir Philip and Sir Greg. Over the past century the MRC has been at the forefront of scientific discovery to improve human health.

Professor Savill continued, “It is with great pleasure that I, along with the MRC’s Council, can recognize those that have contributed so significantly to the transformation of healthcare and the advancement of the way the research community collaborates and innovates.”

Sir Philip said, “I am deeply honored to accept this award from the Medical Research Council. The MRC has given me tremendous support over the past 35 years for the research that I have carried out in Dundee and I am happy that, with the support of the 45 PhD students and 65 postdoctoral researchers who have worked with me over this period, I have been able to make discoveries that are now having a significant impact on human health and wealth creation.”

Sir Philip is Deputy Director of the Division of Signal Transduction Therapy and was Director of the MRC Protein Phosphorylation Unit from the time of its inception in 1990 until April 2012. Both research divisions are situated within the College of Life Sciences at the University of Dundee.

He has devoted his career to studying a cell regulation process called phosphorylation. This endeavour has contributed to what has become the largest and fastest growing area of drug discovery over the past decade.

Sir Philip had been a researcher for 25 years before he first received a phone call from a pharmaceutical company.

“People used to say ‘Oh, what you're doing is interesting but it will never be of the slightest of use for improving health or for wealth creation’,” he recalled.

Phosphorylation is a type of cell regulation that involves the attachment to, or removal of, phosphate groups from proteins, thereby switching their biological functions on or off, or making them more or less stable.

Once thought to be a highly specialized process, Sir Philip’s research helped to show that it was, in fact, universal, regulating almost all aspects of cell life. When phosphorylation goes wrong, it can cause diseases such as cancer, diabetes and arthritis.

That first phone call marked the beginning of Philip’s long and fruitful collaborations with pharmaceutical companies. In 1998 he established the Division of Signal Transduction Therapy, a unique collaboration between researchers from the MRC Protein Phosphorylation Unit, the College of Life Sciences of the University of Dundee and six pharmaceutical companies.

The collaboration employs 200 research and support staff in Dundee and has brought in more than £50 million in funding in its 14-year history. It has helped to accelerate drug development in this area and become a model for collective collaboration between academia and industry. It also led to the creation of biotechnology company Upstate in Dundee in 1999, which is now part of the Merck-Millipore empire.

Therapies based on phosphorylation are one of the largest and fastest growing areas of drug discovery: there are 24 approved drugs that target this process, sales of which were £18 billion globally in 2011, with over 150 others still undergoing clinical trials.

So what has his experience taught him? “I think it shows how important it is to fund ‘blue skies’ research. It can take an awfully long time for research to reach the stage where it becomes obvious how it can be exploited for the benefit of mankind,” he said.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Tuberculosis and Neglected Diseases Targeted by New Centre
New centre to boost the development of drugs to tackle diseases of the developing world.
Thursday, February 14, 2013
Dundee researchers and European collaborators find that anti-diabetes drug fights Alzheimer’s
A potentially exciting breakthrough in the treatment and prevention of Alzheimer’s disease has been made by researchers at the University of Dundee and their international collaborators.
Thursday, November 25, 2010
Drug Discovery Unit, University of Dundee, and DNDi Collaborate to Identify Drug Candidates to Treat Visceral Leishmaniasis
The £1.8m collaboration focuses on the discovery and development of affordable and effective therapies for the disease.
Tuesday, June 30, 2009
Scientific News
NIH Study Finds Calorie Restriction Lowers Some Risk Factors for Age-Related Diseases
Two-year trial did not produce expected metabolic changes, but influenced other life span markers.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Intensity of Desert Storms May Affect Ocean Phytoplankton
MIT study finds phytoplankton are extremely sensitive to changing levels of desert dust.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!